Highlights of This Issue vii

SPECIAL FEATURES

Finding the Right Dose for Cancer Therapeutics—Can We Do Better?
Eric H. Rubin and Keaven M. Anderson
See article p. 1289

Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced Cancer
Amina Zoubeidi, Kim Chi, and Martin Gleave

Targeting the RB-pathway in Cancer Therapy
Erik S. Knudsen and Jean Y.J. Wang

HUMAN CANCER BIOLOGY

High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma

Frequent Downregulation of miR-34 Family in Human Ovarian Cancers

CANCER THERAPY: PRECLINICAL

Comprehensive MicroRNA Profiling for Head and Neck Squamous Cell Carcinomas
Angela R.Y. Hui, Michelle Lenarduzzi, Tiffaney Krushel, Levi Waldron, Melania Pintilie, Wei Shi, Bayardo Perez-Ordonez, Igor Jurisica, Brian O'Sullivan, John Waldron, Pat Gullane, Bernard Cummings, and Fei-Fei Liu

X-Linked Ectodermal Dysplasia Receptor Is Downregulated in Breast Cancer via Promoter Methylation
Vasu Punj, Hitty Matta, and Preet M. Chaudhary

Dasatinib Inhibits the Growth of Molecularly Heterogeneous Myeloid Leukemias

AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer

Blockade of the Extracellular Signal-Regulated Kinase Pathway Enhances the Therapeutic Efficacy of Microtubule-Destabilizing Agents in Human Tumor Xenograft Models
Kazushi Watanabe, Susumu Tanimura, Aya Uchiyama, Toshiaki Sakamoto, Takumi Kawabata, Kei-ichi Ozaki, and Michiaki Kohn
Low-Molecular-Weight Cyclin E Can Bypass Letrozole-Induced G1 Arrest in Human Breast Cancer Cells and Tumors
Said Akli, Tuyen Bui, Hannah Wingate, Anna Biernacka, Stacy Moulder, Susan L. Tucker, Kelly K. Hunt, and Khandan Keyomarsi

A 3′-Untranslated Region Polymorphism in IGF1 Predicts Survival of Non–Small Cell Lung Cancer in a Chinese Population
Mingfeng Zhang, Zhibin Hu, Jinlin Huang, Yongqian Shu, Juncheng Dai, Guangfu Jin, Rong Tang, Jing Dong, Yijiang Chen, Lin Xu, Xinen Huang, and Hongbing Shen

Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells
Zhaojing Zhong, Kyla Driscoll Carroll, Desiree Policarpio, Carla Osborn, Michael Gregory, Rajiv Bassi, Xenia Jimenez, Marie Prewett, Gregory Liebisch, Kris Persaud, Douglas Burtrum, Su Wang, David Surguladze, Stanley Ng, Heather Griffith, Pär Stattin, and Anders Bergh

Low Levels of Phosphorylated Epidermal Growth Factor Receptor in Nonmalignant and Malignant Prostate Tissue Predict Favorable Outcome in Prostate Cancer Patients
Peter Hammarsten, Amar Karaliya, Andreas Jøsefsson, Stina Häggeström Rudolfsson, Pernilla Wikström, Lars Egevad, Torvald Granfors, and Anders Bergh

IMAGING, DIAGNOSIS, PROGNOSIS

MutS Homologue 2 and the Long-term Benefit of Adjuvant Chemotherapy in Lung Cancer

Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography
Nathalie Lassau, Serge Koscienly, Laurence Albige, Linda Chami, Baya Benatou, Mohamed Chebil, Alain Roche, and Bernard J. Escudier

Tobacco Use in Human Papillomavirus–Positive Advanced Oropharynx Cancer Patients Related to Increased Risk of Distant Metastases and Tumor Recurrence

CANCER THERAPY: CLINICAL

Tipifarnib Plus Tamoxifen in Tamoxifen-Resistant Metastatic Breast Cancer: A Negative Phase II and Screening of Potential Therapeutic Markers by Proteomic Analysis
Florence Dalenc, Sophie F. Doisneau-Sixou, Valérie Lauwers-Cances, Karima Chaoui, Odlé Schiltz, Bernard Monsarrat, Thomas Filleron, Nicole Renée, Emilie Malissein, Elise Meunier, Gilles Favre, and Henri Roché

The Predictive Value of HLA Class I Tumor Cell Expression and Presence of Intratumoral Tregs for Chemotherapy in Patients with Early Breast Cancer
Esther M. de Kruijf, Johanna G.H. van Nes, Sja Fontijn, Quirijn R.J.G. Tummers, Hein Putter, Susanne Osanto, Gerrit Jan Liefers, Cornelis J.H. van de Velde, and Peter J.K. Kuppen
Leona Downey, Robert B. Livingston, Maria Koehler, Michael Arbushites, Lisa Williams, Angela Santiago, Roberta Guzman, Ivonne Villalobos, Angelo Di Leo, and Michael F. Press

Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse
Rajul K. Jain, J. Jack Lee, David Hong, Maurie Markman, Jing Gong, Aung Naing, Jennifer Wheler, and Razelle Kurzrock
See commentary p. 1085

Phase I Trial of Pelvic Radiation, Weekly Cisplatin, and 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, NSC #663249) for Locally Advanced Cervical Cancer
Charles A. Kunos, Steven Wagoner, Vivian von Grunigen, Elisa Eldermire, John Pink, Afshin Dowlali, and Timothy J. Kinsella

Randomized Phase III Trial of Gefitinib versus Docetaxel in Non–Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy
Dae Ho Lee, Keunchil Park, Joo Hang Kim, Jong-Seek Lee, Sang Won Shin, Jin-Hyoung Kang, Myung-Ju Ahn, Jin Seok Ahn, Cheolwon Suh, and Sang-We Kim

Phase I Clinical and Magnetic Resonance Imaging Study of the Vascular Agent NGR-hTNF in Patients with Advanced Cancers (European Organization for Research and Treatment of Cancer Study 16041)
Hanneke W.M. van Laarhoven, Walter Fiedler, Ingrid M.E. Desar, Jack J.A. van Asten, Sandrine Marréaud, Denis Lacombe, Anne-Sophie Govaerts, Jan Bogaerts, Peter Lasch, Johanna N.H. Timmer-Bonte, Antonio Lambiase, Claudio Bordignon, Cornelis J.A. Punt, Arnd Heerschap, and Carla M.L. van Herpen

Potential Clinical Significance of a Plasma-Based KRAS Mutation Analysis in Patients with Advanced Non–Small Cell Lung Cancer
Shuhang Wang, Tongtong An, Jie Wang, Jun Zhao, Zhijie Wang, Minglei Zhuo, Hua Bai, Lu Yang, Yan Zhang, Xin Wang, Jianchun Duan, Yuyan Wang, Qingzhi Guo, and Meina Wu
ABOUT THE COVER

Expression of the miR-34 family was found to be frequently reduced in human epithelial ovarian cancer, particularly so in tumors with p53 mutations. The figure shows miR-34a expression (dark blue) in ovarian serous adenocarcinoma as determined by in situ hybridization with locked nucleic acid–modified probes. Immunohistochemistry in serial sections revealed significant inverse correlation between miR-34a and its target MET, an oncogene commonly overexpressed in advanced stages of cancer. For details, see the article by Corney and colleagues on page 1119 of this issue.